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Congenital complete atrioventricular (AV) block occurs in approximately 1 in 20,000 live births and is known to
result in significant mortality and morbidity both during fetal life and postnatally. Complete AV block can occur as a
result of an immune or a non-immune mediated process. Immune mediated AV block is a multifactorial disease, but is
associated with the trans-placental passage of maternal autoantibodies (anti-Ro/SSA and/or anti-La/SSB). These
autoantibodies attach to and subsequently damage the cardiomyocytes and conduction tissue in susceptible fetuses. In
this report, we examine the evidence in reference to means of assessment, pathophysiology, and potential prenatal
therapy of atrioventricular block.
 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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Figure 1. Normal M mode. The cursor is aligned through the atrial
and ventricular myocardium. This is a normal M mode recording
demonstrating 1:1 AV conduction. AV, atrioventricular; A, atrial; V,
ventricular.
Abbreviations
A atrial
AA ascending aorta
AV atrioventricular
AVCTI atrioventricular contraction time interval
CTD connective tissue disease
ECG electrocardiogram
EFE endocardial fibroelastosis
IVC inferior vena cava
IV intravenous
LA left atrium
LAI left atrial isomerism
LV left ventricle
LVOT left ventricular outflow tract
MCG magnetocardiography
MV mitral valve
RA right atrium
RPA right pulmonary artery
SLE systemic lupus erythematosis
SP spine
SVC superior vena cava
TV tricuspid valve
V ventricular
VSD ventricular septal defect
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ATRIOVENTRICULAR BLOCK DURING FETAL LIFEIntroduction
Congenital complete atrioventricular (AV)block is defined as the dissociation of atrial
and ventricular contractions which occurs in
approximately 1 in 20,000 live births [1–3]. This
causes a significant drop in the ventricular rate
which may cause fetal cardiac failure, including
fetal hydrops. Complete AV block is associated
with a risk of intrauterine or postnatal demise
and the optimal prenatal therapy for affected
fetuses has proven controversial. Congenital
complete AV block may result from either an
immune or non-immune mediated process. It
can be associated with underlying structural heart
disease or can develop in association with a
multifactorial, autoimmune process, associated
with the trans-placental transfer of maternal
autoantibodies. These autoantibodies are directed
against Ro/SSA and La/SSB antibodies expressed
on the fetal cardiomyocytes of susceptible fetuses.
Congenital complete AV block of either is
associated with significant prenatal mortality and
postnatal morbidity and thus remains an area of
major clinical interest [1,4–8]. The aims of this
report are to review atrioventricular block
occurring during fetal life, with particular
reference to means of assessment, causation and
prenatal therapy.Assessment of fetal atrioventricular block
Postnatally, the 12 lead electrocardiogram (ECG)
recording is the gold standard for assessment and
diagnosis of rhythm disturbance. During fetal life
it is difficult to extract the fetal ECG because of
the distance of the fetus to the maternal skin,
possible insulating properties of vernix, and the
small size of the fetus, all of which contribute to
low voltages. Fetal movement, interference from
the maternal heart rate and maternal muscular
contraction further contribute to the difficulties
in extracting a fetal ECG [9]. Despite these
limitations, this method has been used to
accurately record the fetal ECG. An alternative
technique, fetal magnetocardiography (MCG)
has been used to detect the magnetic fields caused
by electrical signals in the fetal heart. This
technique is used in a research setting and
typically depends on a magnetically-shielded
room to be feasible [10–12].
Thus, echocardiography remains the principal
technique for assessing AV synchrony or arrhyth-
mias in the fetus. Mechanical assessment by M
mode infers electrical activity by demonstrating
sequential contraction of the atrial and ventricular
myocardium by aligning the cursor simulta-
neously through both myocardial walls [13]
(Fig. 1). The M mode technique can be used to
confirm normal sinus rhythm, tachycardia and
fetal bradycardia, including complete AV block
[14] (Fig. 2). Tissue Doppler and pulsed Doppler
techniques are also widely employed [15–17].
Figure 2. M mode – complete AV Block. This M mode recording
demonstrates a slow ventricular rate and complete dissociation
between atrial and ventricular contractions (CAVB). CAVB, complete
atrioventricular block; A, atrial; V, ventricular.
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conventional M mode tracing, but measuring
and determining the presence of lower grade AV
block is challenging and Doppler methods are
routinely incorporated to make this assessment.
It should be noted that echocardiographic tech-
niques cannot be used to measure time intervals
such as the QT interval, which can be evaluated
by magnetocardiography [12,18].
In an effort to detect lower grade AV block,
attention has focused on the measurement of the
mechanical PR interval by Doppler techniques,
including pulsed wave (PW) Doppler or tissue
Doppler. This is of particular interest in fetuses
at an increased risk of developing heart block.Figure 3. Normal AVCTI. The AVCTI is a reflection of the postnatal
electrocardiographic PR interval. The cursor is aligned simulta-
neously through the mitral inflow and left ventricular outflow. The
Doppler time interval between the onset of the A wave (atrial systole)
and the onset of the ejection outflow Doppler (ventricular systole) is
measured (ms). AVCTI, atrioventricular contraction time interval.The time between atrial and ventricular systole
is known as the atrioventricular contraction time
interval (AVCTI) and is a mechanical representa-
tion of the traditional postnatal electrical PR inter-
val (Fig. 3). Within the same cardiac cycle, the
AVCTI is obtained by aligning the gated PW
Doppler cursor simultaneously across an inflow
and outflow, for example, left ventricular outflow
tract (LVOT) and mitral valve. The Doppler time
interval is measured between the onset of the A
wave (atrial systole) and the onset of the ejection
outflow Doppler (ventricular systole). Alternative
methods involve aligning the Doppler cursor
through a pulmonary vein and right pulmonary
artery (RPA) or ascending aorta (AA) and superior
vena cava (SVC), and measuring the time interval
from the onset of the retrograde venous A wave to
the onset of the outflow Doppler [11,19]. Although
useful, AV time intervals are derived from flow
and, as such, the accuracy of the measurements
are influenced by myocardial intrinsic properties,
ventricular loading conditions, fetal heart rate
and the speed of pulse wave propagation [16].
Normative fetal mechanical PR interval reference
ranges have been published. In addition, AVCTI
values have been shown to be increasingly related
to gestational age, and specifically, MV/LVOT
time intervals are influenced independently by
the fetal heart rate [16,20–23]. The various meth-
ods of assessing the AVCTI prenatally have been
compared to the postnatal electrical PR interval.
A study by Bergman et al. found the most accurate
measurement when compared to the postnatal
ECG was the AA/SVC technique [24]. Although
AVCTIs are influenced by intrinsic myocardial
properties, studies have confirmed that in the
hands of experienced fetal echocardiographers
there is minimal inter-operator variability [22]. It
has been hypothesized that measuring the fetal
mechanical PR interval by this method may allow
for surveillance and early recognition of fetuses
with lower degrees of AV block, and possible pro-
gression to complete AV block. However, this
remains controversial [25].Complete atrioventricular block associated
with structural heart disease
Certain structural heart defects are known to
predispose to the development of prenatal con-
genital complete AV block. The most frequent car-
diac lesions associated with complete AV block
are isomerism of the left atrial appendages (LAI)
and discordant atrioventricular connections
(Figs. 4 and 5). A retrospective study of 116 fetuses
Figure 4. Left atrial isomerism – situs. This fetal echocardiographic
image demonstrates cardiac situs in the presence of LAI. The spine
lies posteriorly with one rib surrounding the fetal thorax. The
stomach lies to the left. The aorta lies anteriorly and to the same side
of the spine as the azygous vein. There is azygous continuation due to
interruption of the IVC. LAI, left atrial isomerism; IVC, inferior vena
cava.
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chamber echocardiographic view of the fetal heart. There is reversal
of normal AV valve offsetting, indicating AV discordance. AV,
atrioventricular; VA ventriculoarterial.
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ATRIOVENTRICULAR BLOCK DURING FETAL LIFEdiagnosed with complete AV block, detected an
associated congenital structural heart defect in
over 50%. Of these affected fetuses, greater than
60% were associated with LAI [26].
LAI is a multisystem disorder of visceral lateral-
ity, characterized by the presence of morphologi-
cal, bilateral left atrial appendages. A spectrum of
cardiac abnormalities can occur in association
with LAI, for example, isolated interruption of
the inferior vena cava (IVC) with azygous continu-
ation to the SVC, defects of the atrioventricularjunction and outflow tract abnormalities. Systemic
manifestations may include abnormal pulmonary
lobar morphology with bilateral left bronchial
anatomy, abnormally positioned abdominal vis-
cera including malrotation of the bowel, biliary
atresia and polysplenia or, rarely, asplenia which
may result in altered or suboptimal immune func-
tion. In normal cardiac situs, the sinus node is a
morphologically right atrial structure. Thus, in a
diagnosis of LAI, the sinus node by definition is
abnormally positioned, hypoplastic or absent,
often resulting in a sinus bradycardia or complete
AV block. The combination of LAI and complete
AV block prenatally has a very poor prognosis,
particularly in the presence of fetal hydrops, with
mortality rates by term reported as high as 100%
[26]. This is a condition with very few therapeutic
options and the prognosis does not seem to be
improving with advances in fetal cardiology
[4,6,8,27].
A diagnosis of discordant atrioventricular (AV)
connections may be made during routine fetal
echocardiography. The four chamber view of
the heart is assessed in a cross sectional view
through the fetal thorax. This traditional four
chamber view demonstrates reversal of the nor-
mal pattern of offsetting of the atrioventricular
valves (Fig. 5). Discordant AV connections can
occur in isolation or with associated intra-cardiac
defects, for example, ventricular septal defects
(VSDs), and outflow tract obstruction. Morpho-
logically, the atrial and inlet portion of the ven-
tricular septum are maligned, disrupting the
normal conduction axis, potentially leading to
progressive AV block and subsequent complete
AV block, pre or postnatally [28].
In addition to LAI and discordant AV connec-
tions, complete AV block can occur in association
with more common structural heart defects,
including tetralogy of Fallot, right ventricular
hypoplasia, double inlet left ventricle, VSD, coarc-
tation with VSD, and multiple rhabdomyomas [26].Complete atrioventricular block with normal
cardiac connections
In contrast to complete AV block associated with
structural heart disease, immune mediated com-
plete AV block most commonly occurs with a
structurally normal heart. Functional abnormali-
ties may coexist, including cardiomegaly, ventric-
ular hypertrophy, impaired ventricular function,
and atrioventricular valve regurgitation which
can contribute to pericardial effusions and, in
severe cases, fetal hydrops. Immune mediated
Table 1. Complete atrioventricular block.
Authors Study design Inclusion
criteria
AV block Treatment Prenatal
outcome
Postnatal
outcome
Copel et al.
[45]
Prospective Antibody +ve
n = 5
CAVB n = 4 Dexamethasone n = 4 – CAVB n = 4
Intermittent
CAVB and
second degree
AV block n = 1
Dexamethasone n = 1 – CAVB at term,
reverted to
second degree
AV Block
postnatally n = 1
Yamada
et al. [51]
Prospective Antibody +ve
n = 2
CAVB n = 1 Prednisolone and
Dexamethasone
– CAVB n = 1
Friedman
et al. [38]
‘PRIDE’
Prospective,
multicenter,
observational
Antibody +ve
n = 98 (pre
study maternal
steroids
excluded)
CAVB n = 1 Dexamethasone Fetal
hydrops –
TOP
–
CAVB n = 1 Dexamethasone CAVB CAVB Paced
CAVB n = 1 Dexamethasone Fetal
Hydrops –
TOP
–
Jaeggi et al.
[39] UOG
Case Study Antibody +ve
n = 1
CAVB at
21 weeks
gestation
Dexamethasone 22 weeks
second
degree AV
block
24 weeks
First degree
AV block
32 weeks
CAVB and
EFE
CAVB not
paced
Jaeggi et al.
[39] Circ
Retrospective Antibody +ve
n = 33
CAVB n = 33 Dexamethasone n = 12 IUD n = 1 CAVB n = 11
Dexamethasone/b
Stimulation n = 8
TOP/IUD
n = 2
CAVB n = 5 IFD
n = 1
b Stimulation n = 1 – CAVB/NND
n = 1
Dexamethasone/IVIG n = 1 – CAVB n = 1
Jaeggi et al.
[39] Circ
Retrospective Antibody ve
n = 4
CAVB n = 4 No therapy n = 2 – NND n = 1
CAVB n = 1
(paced)
Dexamethasone/b
Stimulation n = 2
CAVB n = 2
(paced)
Sonesson
et al. [40]
Prospective Antibody +ve
n = 24
CAVB n = 1
(preceded by
first degree AV
block)
Betamethasone n = 1 – CAVB n = 1
Lopes et al.
[26]
Retrospective Antibody +ve
n = 42
Antibody ve
n = 15
CAVB n = 35
CAVB
(preceded by
second degree
AV block) n = 9
Dexamethasone ± b
Stimulation n = 4 unspecified
cases
IUD n = 5 Alive n = 52
Fesslova
et al. [42]
Multicenter,
retrospective
Antibody +ve
n = 28
CAVB n = 28 Dexamethasone n = 18 IUD n = 1 CAVB n = 17
Dexamethasone + b
Stimulation n = 2
– CAVB n = 1
NND n = 1
Isoproterenol n = 1 – NND n = 1
No therapy n = 7 IUD n = 1 CAVB n = 6
Eliasson
et al. [47]
Multicenter,
multinational,
retrospective
n = 175 (80%
Ro/La antibody
+ve)
CAVB n = 146 Dexamethasone/
Betamethasone n = 54
TOP n = 1
IUD n = 6
(therapy)
NND n = 3
(therapy) n = 7
(no therapy)
Alive at 1 month
n = 53 (therapy)
n = 85 (no
therapy) 11 lost
to f/u
No therapy n = 92 IUD n = 9
(no
therapy)
CAVB
(preceding
second degree
AV block)
n = 14
Dexamethasone/
Betamethasone n = 6
–
No therapy n = 8 –
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Table 1. (continued)
Authors Study design Inclusion
criteria
AV block Treatment Prenatal
outcome
Postnatal
outcome
Izmirly et al.
[52]
Case
controlled
study
Antibody +ve
n = 201 cardiac
manifestations
n = 50
Second degree
AV block/
CAVB n = 43
(out of 50 with
cardiac
manifestations)
Dexamethasone/
betamethasone n = 48 of 50
hydroxychloroquine n = 7 of
50
– No outcomes
documented
Tunks et al.
[55]
Retrospective Antibody +ve
n = 33
CAVB n = 4
(HCQ
prophylaxis
n = 0)
Dexamethasone n = 4 CAVB n = 3 CAVB n = 4
(Paced n = 3)CAVB
preceded
by 1st AV
block n = 1
Kaaja and
Julkunen
[57]
Prospective Antibody +ve
n = 8
CAVB n = 1 IVIG – CAVB n = 1
Sinus rhythm
n = 7
IVIG/Steroids – Sinus rhythm
n = 7
Pisoni et al.
[58]
Multicenter,
prospective,
observational
Antibody +ve
n = 24
Sinus rhythm
n = 24
IVIG/Hydrocortisone
prophylaxis n = 15
CAVB n = 3
(TOP n = 2)
Alive n = 12
CAVB n = 1
No prophylaxis n = 9 CAVB n = 1
(TOP)
Alive n = 8
Friedman
et al. [29]
Multicenter,
prospective,
open-label
clinical trial
Antibody +ve
n = 20
Sinus rhythm
n = 20
IVIG prophylaxis n = 20 CAVB n = 3
(n = 1
preceded
by 2nd AV
block)
CAVB n = 3
(despite
additional
dexamethasone)
Sinus
rhythm
n = 17
Sinus rhythm
n = 17
Jaeggi et al.
[3]
Prospective Antibody +ve
n = 40
CAVB n = 35
(sinus rhythm
n = 3)
Steroids ± Salbutamol ± IVIG
n = 25
IUD n = 1 IFD n = 2, Alive
n = 22
No therapy n = 4 TOP n = 2
IUD n = 1
Alive n = 1
Not documented n = 6 – Alive n = 6
AV, atrioventricular; CAVB, complete; AV, block; TOP, termination of pregnancy; EFE, endocardial fibroelastosis; IUD, intrauterine demise; IFD,
infant death; NND, neonatal death; f/u, follow up; IVIG, intravenous immunoglobulin.
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ATRIOVENTRICULAR BLOCK DURING FETAL LIFEcongenital complete AV block is a passively
acquired, autoimmune disease associated with
the trans-placental passage of maternal autoanti-
bodies to the developing fetus. In susceptible
fetuses, the autoantibodies attach to the ribonu-
cleotide proteins (antibodies) which are expressed
on cardiomyocytes of the fetal myocardium, in
particular: 52 kD Ro/SSA (Ro52); 60 kD Ro/SSA
(Ro60) and 48 kD La/SSB (La48). This immune
process results in inflammation of the fetal con-
duction tissue and myocardium with resultant
progressive and irreversible fibrosis. In severe
cases that result in intrauterine demise, post-mor-
tem assessment has identified necrosis, fibrosis,
and calcification of the fetal myocardium and con-
duction tissue [29]. Long QT syndrome may result
in complete AV block within a structurally normal
heart. The QT interval may be so prolonged that
atrial depolarisation occurs during the refractory
period of the ventricle so that the atrial impulse
does not result in ventricular contraction. In thisclinical situation parental ECGs may be helpful.
In contrast to the PR interval, the QT interval can-
not be measured by fetal echocardiography, but
can be assessed by fetal MCG [12,18,30].
Anti-Ro/SSA and La/SSB antibodies are com-
monly associated with maternal connective tissue
disease, but have been detected in the asymptom-
atic, general population. Within the population of
women seropositive for anti-Ro/SSA or anti-La/
SSB antibodies, it is estimated that only 2–3% of
offspring will develop congenital AV block or
abnormalities of the myocardium [9]. However, if
a previous child has been affected the recurrence
risk in subsequent pregnancies increases to 17–
20% [1,31,32]. Thus, it can be hypothesized that
the presence of autoantibodies may be associated
with the disease process but is not the solitary
causative factor resulting in irreversible damage
to the fetal heart. There are as yet unrecognized
factors which may contribute to the pathogenesis
of immune mediated complete AV block, and
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environmental factors. This hypothesis is corrobo-
rated by a study in which 85% of mothers with
children with congenital complete AV block were
asymptomatic for connective tissue disease prior
to conception. In addition, 98% of the women in
whom fetal complete AV block was detected had
a previously healthy child with no evidence of a
conduction disorder [3]. There are reports of
delayed seroconversion in previously asymptom-
atic women several years after delivering a child
affected by congenital complete AV block [26].
This highlights the importance of appropriate
counselling of all women in whom a fetus is
affected by complete AV block, including referral
for assessment by specialists in connective tissue
disease.Treatment of complete AV block
Although complex, the pathophysiology of
immune mediated congenital complete AV block
involves an immune mediated inflammatory pro-
cess which damages the conduction tissue and
myocardium of the developing heart. In order to
directly target and potentially halt this destructive
process, anti-inflammatory medications and
immune modulators have been utilized. Many
studies are anecdotal, retrospective with small
study numbers, and vary with respect to whether
the aim is prevention of AV block in the fetus or
treatment of the fetus who has developed signs
of complete or lesser degrees of AV block. The
most common therapies include maternal steroids,
b stimulation with salbutamol, IV immunoglobulin
and hydroxychloroquine. Other less common
maternal therapies include: B cell depletion ther-
apy [33], azathioprine [34], cyclophosphamide
[35], and plasmapheresis [36,37], Treatment may
be subdivided according to the degree of AV block,
and may be classed as prophylactic or therapeutic.Complete atrioventricular block
There is no robust evidence to suggest all cases
of complete AV block are preceded by lower
degrees of AV block. In the presence of lower
degrees of AV block, progression to complete AV
block can occur rapidly over a short period of
time, often within days [25,38–40]. Once this
immune reaction has occurred, complete AV block
has not been reported to shown signs of revers-
ibility or evidence of spontaneous reversion to
sinus rhythm despite maternal medical therapy
[38,41–43]. Prednisolone, betamethasone anddexamethasone have been used as therapy in
many women with a positive antibody status.
Dexamethasone, a fluorinated steroid, may act
by reducing the maternal autoantibody load, but
does not directly act to protect the fetal myocar-
dium and conduction tissue from the destructive
action of the autoantibodies [44]. However, mater-
nal steroids have been associated with resolution
of fetal hydrops when associated with complete
AV block, which may be related to an acute
inflammatory process resulting in a myocarditis
[42,45]. Table 1 summarizes studies of the treat-
ment and outcome of prenatally detected com-
plete AV block.
The indications for treatment of complete AV
block are controversial. Some data has suggested
a beneficial effect of dexamethasone and salbuta-
mol on outcome [43]. However, this paper used
historic controls, and other groups have suggested
that the apparent effect of therapy may be a time
era effect [46]. Recently, a European multinational
retrospective study confirmed that steroid therapy
was used in 38% of affected cases but that this did
not have a positive impact on intrauterine sur-
vival, postnatal survival or development of late
cardiomyopathy [47]. Of mothers treated with ste-
roids, 15% developed an adverse fetal or maternal
side effect [47]. That study did not address the
impact of additional therapy with b stimulation
and confirmed that choice of therapy was more
related to the institution than the condition of
the fetus [43]. Groves et al. demonstrated that
maternal salbutamol therapy increased the fetal
ventricular rate and subsequently improved fetal
myocardial function [48]. Conversely, other stud-
ies have suggested that b stimulation does not
increase the fetal heart rate significantly but when
the baseline fetal heart rate was lower than the
controls there was no further reduction in the ven-
tricular rate [43]. Use of maternal salbutamol has
been associated with prolongation of gestation in
affected fetuses [49].Second degree AV block
Traditional M mode assessment may detect
second degree AV block. In particular, type 2 second
degree AV block can be detected by demonstrating
two atrial contractions to every ventricular contrac-
tion with a fixed relationship between atrial and
ventricular beats. However, differentiating second
degree and complete AV block by M Mode assess-
ment can be extremely difficult. Alternatively,
Doppler techniques can be used to determine the
time intervals between atrial and ventricular con-
tractions including a Wenckebach pattern [50].
Table 2. Second degree atrioventricular block.
Authors Study design Inclusion
criteria
AV block Treatment Postnatal outcome
Copel
et al.
[45]
Prospective Antibody +ve
n = 5
Second degree AV
block n = 1
Dexamethasone Sinus rhythm n = 1
Second degree AV
block and
intermittent CAVB
n = 1
Dexamethasone CAVB with subsequent
second degree AV block
(not paced) n = 1
Yamada
et al.
[51]
Prospective Antibody +ve
n = 2
Second degree AV
block n = 1
Prednisolone and
Dexamethasone
Second degree AV
block at term n = 1
Sonesson
et al.
[40]
Prospective Antibody +ve
n = 24
Second degree AV
block n = 1
Betamethasone First degree AV block at
term n = 1
Lopes
et al.
[26]
Retrospective Antibody +ve
n = 42
Antibody ve
n = 15
Second degree AV
block n = 22
No therapy Sinus rhythm n = 4
Second degree AV
block n = 9
CAVB n = 9
Eliasson
et al.
[47]
Multicenter,
retrospective
n = 175 Second degree AV
block n = 29
Dexamethasone/
betamethasone n = 13
Outcome see CAVB
table*
No therapy n = 16
Izmirly
et al.
[52]
Case controlled
study
Antibody +ve
n = 201
Cardiac
Manifestations
n = 50
Second degree AV
block (or CAVB)
n = 43 of 50
Dexamethasone n = 26
Betamethasone n = 22
Hydroxychloroquine n = 7
No outcomes
documented*
Friedman
et al.
[29]
Multicenter,
Prospective,
Open-Label
Clinical Trial
Antibody +ve
n = 20
Second degree AV
block n = 1
Prophylaxis IVIG/
hydrocortisone Treatment
with dexamethasone
CAVB n = 1
AV, atrioventricular; SR, sinus rhythm; CAVB, complete atrioventricular block; IVIG, intravenous immunoglobulin.
* See CAVB Table.
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ATRIOVENTRICULAR BLOCK DURING FETAL LIFEIn contrast to complete AV block, there is some
evidence that second degree AV block may poten-
tially be reversible (Table 2) and some cases of
second degree AV block may not progress to com-
plete AV block [40,45,51]. Lopes et al. retrospec-
tively identified 22 fetuses affected by second
degree AV block. None of the mothers received
medical therapy and subsequently, nine fetuses
remained in second degree AV block; four
reverted to sinus rhythm, and a further nine pro-
gressed to complete AV block by term [26]. Other
studies include very small numbers of fetuses
affected by second degree AV block. Thus, the
efficacy of maternal steroid therapy for the treat-
ment of second degree AV block remains contro-
versial [38,45,51–54]. Table 2 summarizes studies
reviewing the treatment and outcomes of prena-
tally detected second degree AV block.First degree AV block
It is reported that approximately 30% of women
who are seropositive for anti-Ro/SSA 52 Kd exhibit
transient first degree AV block in the fetus, withoutprogression to higher degrees of AV block [40].
Screening high risk pregnancies by measuring the
fetal AVCTI (mechanical PR interval) has been pro-
posed to allow early recognition and potential
intervention for first degree AV block. Normal
ranges, using a variety of techniques have been
published [11,22]. The fundamental clinical deci-
sion is whether treatment will be initiated following
detection of prolongation of the AVCTI or whether
the fetus will be observed to check that the AVCTI
spontaneously normalizes. The approach in stud-
ies has varied between observation [40] and active
therapy including dexamethasone, hydroxychloro-
quine and IV immunoglobulin [3,52,55]. Even the
larger studies had a sample size of less than ten
fetuses. Tunks et al. treated five antibody positive
women, in whom the fetus demonstrated first
degree AV block, with a combination of dexameth-
asone, IV immunoglobulin or hydroxychloroquine.
Their results showed that one fetus progressed to
complete AV block while the other four remained
in first degree AV block or reverted to sinus rhythm
[55]. Table 3 summarizes studies reviewing the
treatment and outcomes of prenatally detected
complete AV block.
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Table 3. First degree atrioventricular block.
Authors Study Design Inclusion
Criteria
AV Block Treatment Prenatal
Outcome
Postnatal
Outcome
Sonesson
et al.
[40]
Prospective Antibody +ve
n = 24
First degree AV
block n = 8
Nil – Sinus rhythm
n = 5 First
degree AV block
n = 3
First degree AV
block at 22 weeks
gestation n = 1
Dexamethasone Sinus rhythm
within 2 days of
therapy n = 1
Sinus rhythm
n = 1
Normal prenatal
PR interval n = 1
– – First degree AV
block (preterm
32 weeks) n = 1
Izmirly
et al.
[52]
Case control
study
Antibody +ve
n = 201
Cardiac
manifestations
n = 50
First degree AV
block n = 3
Dexamethasone n = 2 Sinus rhythm
n = 2
Sinus rhythm
n = 2
No therapy n = 1 – First degree AV
block n = 1
Tunks
et al.
[55]
Retrospective Antibody +ve
n = 33
First degree AV
block n = 5
Dexamethasone n = 1 CAVB n = 1 CAVB
Dexamethasone/
IVIG n = 1
Alternate first
and second
degree AV block
n = 1
First degree AV
block
Hydroxychloroquine/
dexamethasone n = 1
First degree AV
block n = 1
Sinus rhythm or
first degree AV
blockDexamethasone n = 2 First degree AV
block n = 2
Jaeggi
et al. [3]
Prospective Antibody +ve
n = 40
First degree AV
block n = 2
Steroids/IVIG n = 1 – Alive
No therapy n = 1 – Alive
AV, atrioventricular; IVIG, intravenous immunoglobulin; CAVB, complete atrioventricular block.
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AV block
Studies have been published on the use of ther-
apies to prevent development of AV block in high
risk pregnancies. The treatments used include
hydroxychloroquine, IV immunoglobulin, plasma-
pheresis, azathioprine, and B cell depletion. Most
data relates to the use of hydroxychloroquine
and IV immunoglobulin. Hydroxychloroquine
(Plaquenil) is an immune modulator with anti-
inflammatory effects. A retrospective, case con-
trolled study demonstrated a trend towards a
lower incidence of rhythm or functional cardiac
complications in fetuses exposed to hydroxychlo-
roquine compared to those who were not. The
study defined exposure to hydroxychloroquine as
maternal therapy P200 mg per day. This study
did not reach statistical significance but the overall
OR was 0.44 (95% CI 0.19–1.03; p = 0.06) [52]. This
was corroborated by a single center, retrospective
study by Tunks et al. (n = 33) [55], which suggested
that exposure to hydroxychloroquine in the pre-
conception phase or during pregnancy, may
reduce the incidence of complete AV block in high
risk fetuses. Of the fetuses who did not develop
any degree of AV block (n = 25), thirteen wereexposed to hydroxychloroquine during the preg-
nancy. In the cohort of fetuses who developed
AV block (n = 8) only one was exposed to hydroxy-
chloroquine. All fetuses who developed complete
AV block were treated with dexamethasone, but
there was no reversion to lower degrees of AV
block. A significant proportion of the mothers
receiving hydroxychloroquine in this study was
concurrently treated with low dose prednisolone,
thus carrying implications for the interpretation
of the results [55]. Both studies included women
who were seropositive for anti-Ro/SSA or La/
SSB, proven to be affected by systemic lupus
erythematosus (SLE) or had a previous child
affected by congenital complete AV block, thus
representing a high risk population [52,55].
Murine models have hypothesized that IV
immunoglobulin may prevent trans-placental pas-
sage of anti-Ro/SSA and anti-La/SSB antibodies
by non-specifically blocking placental Fc receptors,
and therefore preventing the detrimental antibody
effects on the developing fetal myocardium
[56]. Kaaja and Julkunen [57] prophylactically
administered a combination of IV immunoglobu-
lin and prednisolone to women (n = 7) in whom a
previous pregnancy was affected by complete AV
block. The fetuses of women treated with combina-
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ATRIOVENTRICULAR BLOCK DURING FETAL LIFEtion therapy remained in sinus rhythm at term.
Conversely, the single fetus whose mother was
administered IV immunoglobulin in isolation
(patient declined prednisolone) developed com-
plete AV block [57]. However, more recent pro-
spective studies have not confirmed benefit. In a
prospective, multicenter trial by Pisoni et al. [58]
a cohort of antibody-positive women (n = 15) were
treated prophylactically with hydrocortisone and
IV immunoglobulin. In the treatment cohort, three
fetuses developed complete AV block, and two out
of the three pregnancies were interrupted. How-
ever, in the non-treatment cohort (n = 9) only one
fetus developed complete AV block. They con-
cluded that the dose and frequency of IV immuno-
globulin was insufficient to prevent AV block in
the fetus [58]. This was corroborated by a second
multicenter, prospective study by Friedman et al.
[29] who prescribed low dose immunoglobulin to
mothers who were positive for anti-Ro/SSA anti-
bodies. This failed to prevent the development of
complete AV block in high-risk fetuses or reduce
the level of maternal antibody titres. The trial
was stopped early due to the development of com-
plete AV block in three of the first 19 patients
recruited. The study speculated that a higher dose
of IV immunoglobulin might be more effective atTable 4. Prophylaxis for AV block.
Authors Study design Inclusion
Criteria
Prophylaxis
Izmirly
et al. [52]
Case controlled
study
Antibody
+ve n = 50
Dexamethasone
Betamethasone n
Hydroxychloroqu
Tunks et al.
[55]
Retrospective Antibody
+ve n = 33
Hydroxychloroqu
prednisolone n =
No therapy n = 1
Kaaja and
Julkunen
[57]
Prospective Antibody
+ve n = 8
IVIG n = 1
IVIG/Steroids n =
Pisoni et al.
[58]
Multicenter,
prospective,
observational
Antibody
+ve n = 24
IVIG/Hydrocortis
prophylaxis n = 1
No prophylaxis n
Friedman
et al. [29]
Multicenter,
Prospective,
Open–Label
Clinical Trial
Antibody
+ve n = 20
IVIG prophylaxis
AV, atrioventricular; IVIG, intravenous immunoglobulin; CAVB, complete a
* See CAVB Table.preventing complete AV block [29]. These studies
are summarized in Table 4.
In a further attempt to provide more accurate
risk stratification for the development of congeni-
tal complete AV block, the assessment of plasma
levels of maternal anti-Ro/SSA and anti-La/SSB
have been studied. Jaeggi et al. [3] described an
association between high levels of anti-Ro/SSA
(>100U/ml) and the development of complete AV
block [3]. No fetuses prenatally exposed to mater-
nal anti-Ro/SSA levels <50 U/ml developed com-
plete AV block. Levels of maternal anti-La/SSB
showed no association with AV block. However,
57% of neonates with prenatal exposure to mater-
nal anti-La/SSB levelsP100 U/ml developed signs
of non-cardiac neonatal lupus [3]. These findings
were not corroborated by Tunks et al. [55] whose
study suggested there was no correlation between
prenatal exposure to high levels of maternal anti-
Ro/SSA antibody titres and the development of
complete AV block. However, they suggested pre-
natal exposure to elevated levels of anti-La/SSB
was pathognomonic of developing complete AV
block [55]. It is difficult to compare these two
studies as the demographics and inclusion criteria
of the two studies vary significantly. Despite
conflicting opinions, there are proposals that allAV Block Prenatal
Outcome
Postnatal
Outcome
n = 26
= 22
ine n = 7
1st AV Block n = 3
2nd AV block (or
CAVB) n = 43
– No outcomes
documented⁄
ine or
16
1st AV Block n = 1 – Sinus rhythm
n = 25
1st AV Block
n = 1
7 CAVB n = 4 – CAVB n = 4
1st AV Block n = 3 1st AV Block
n = 3
CAVB n = 1 – CAVB n = 1
7 Sinus rhythm
n = 7
– Sinus rhythm
n = 7
one
5
CAVB n = 3 TOP
n = 2
CAVB n = 1 Alive
n = 12
= 9 CAVB n = 1 TOP
n = 1
Alive n = 8
n = 20 CAVB n = 3 (n = 1
preceded by 2nd
AV block)
– CAVB n = 3
(despite
additional
dexamethasone)
Sinus rhythm
n = 17
– Sinus rhythm
n = 17
trioventricular block; TOP, termination of pregnancy.
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trimester for the presence of autoantibodies and
with particular emphasis on anti-Ro/SSA and
anti-LA/SSB levels [27].Approach to management
Due to the low incidence of complete AV block
in the general population, studies are mainly
observational, retrospective and involve small
cohorts of patients. The team from Toronto Sick
Children’s Hospital have published their guid-
ance for the management of varying degrees of
congenital AV block. In their protocol, Jaeggi
et al. [43] advise no therapy in the presence of iso-
lated first degree AV block, but in the presence of
second degree AV block or complete AV block, a
course of maternal steroids is recommended. If
the fetal ventricular escape rate is 655 bpm,
supplementary maternal salbutamol therapy is
considered. In the presence of isolated fetal myo-
cardial endocardial fibroelastosis (EFE), maternal
IV immunoglobulin is administered at two to
three weekly intervals prenatally. Postnatally, the
affected child would also be treated with a course
of IV immunoglobulin [43].Approach and policy at our centre
In our institution, Evelina London, we do not
currently recommend cardiac referral of mothers
with connective tissue disease (CTD) whose       
       P
Yes (17% Risk)
Referral to Fetal 
Cardiology
2D Echo, Function, 
AVCTI, M mode, EFE 
Previou
Child CA
Increased 
AVCTI
Anti Ro/
Status
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weekly r/v 
2:1 AV Bl
Consider 
Dexamethasone
No treatment - 
observe
D
Figure 6. Fetal cardiology assessmentanti-Ro/La antibody status is negative, unless
there is evidence of fetal heart block on the obstet-
ric anomaly scan. Some mothers with CTD are
referred with unknown antibody status. In this sit-
uation, anti-Ro/SSA and La/SSB titres are checked
and, if negative, coupled with a normal echocar-
diogram, then no further cardiac review is under-
taken. For mothers who are known to be anti-Ro
and/or anti-La positive, fetal echocardiography is
undertaken at 18–24 weeks gestational age,
including 2D imaging to confirm structural nor-
mality, pulsed wave Doppler, color flow Doppler
and M mode assessment to confirm AV syn-
chrony. To identify first degree AV block, the
AVCTI (ms) is measured by pulsed wave Doppler
and compared to normative values. The presence
of maternal anti-Ro/SSA and La/SSB antibodies
is recorded in a bid to provide prognostication,
and we recently introduced measurement of
antibody titres. Tissue Doppler imaging is not
routinely used in our assessment. In the presence
of a structurally normal fetal heart and an AVCTI
within normal limits for gestational age, two fur-
ther assessments are arranged at regular intervals
(Fig. 6). The detection of first degree AV block
would warrant closer follow-up to assess for pro-
gression to higher degrees of AV block or rever-
sion to a normal AVCTI. It is not our policy to
treat isolated first degree AV block. Detection of
second degree AV block would merit consider-
ation of maternal dexamethasone therapy (4 mg
daily initially, followed by a tapering regimen) to           Negative 
ositive   
       No (2% Risk)
2D Echo, Function, 
AVCTI, M mode, EFE 
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of maternal autoimmune disease.
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ATRIOVENTRICULAR BLOCK DURING FETAL LIFEgauge whether this is associated with reversion to
a lower degree of AV block. Depending on the
fetal response, this dose is tapered with the aim
of minimizing potential side effects of dexametha-
sone for the fetus and mother.
If there is complete AV block, then the decision
to give therapy depends on additional findings. If
there is no evidence of fetal hydrops, good ven-
tricular function and no echogenicity of the ven-
tricular myocardium, then our policy is for close
review without initiation of therapy. If, however,
there is hydrops, subjective evidence of reduced
ventricular function and/or echogenicity of the
myocardium (which may suggest endocardial
fibroelastosis) then maternal dexamethasone
would be seriously considered. Fetal hydrops
would be an indication for active therapy which
would include dexamethasone coupled with sal-
butamol, particularly if the fetal ventricular rate
is very low. Slow release salbutamol is adminis-
tered orally, with baseline monitoring of maternal
electrolytes prior to therapy. Whether treatment is
given or not, close fetal cardiological and obstetric
review is warranted to monitor fetal cardiac func-
tion, fetal ventricular rate and signs of hydrops.
Within our unit, we would not recommend
extreme preterm delivery due to its association
with poorer neonatal outcomes [59]. Each case is
considered individually within our multidisciplin-
ary team, ensuring delivery occurs at an optimal
time, in an effort to minimize neonatal morbidity
and mortality.Treatment side effects
When considering prenatal therapy it is impor-
tant to consider the risks and benefits for both
the mother and the developing fetus. Some units
have strongly advocated the use of dexametha-
sone, given the observation of better outcome
[43]. Dexamethasone is associated with maternal
complications such as hypertension, gestational
diabetes and fetal complications, for example, oli-
gohydramnios and detrimental effects on growth
and development [42,47,60,61]. A single dose of
steroids is commonly administered to promote
lung maturation in the preterm infant with threa-
tened preterm labor, but concerns have been
raised regarding the effects of multiple steroid
doses, in particular, the effect on the developing
fetal brain. The National Institute of Health
released a consensus statement, stating there are
no substantiated reports of adverse effects from
a single dose of prenatal steroids, but advised that
multiple courses of steroids should only beadministered within clinical trials [61]. This was
highlighted in the PRIDE study, which advised
that the potential benefits of maternal steroid
therapy must be carefully balanced against the
potential detrimental effects on fetal growth [38].
Regarding neurodevelopment, Brucato et al. [62]
retrospectively examined a cohort (n = 16) of
infants with congenital complete AV block who
had been exposed to high levels of dexametha-
sone in utero. They found no significant intellec-
tual deficiencies in preschool or school age
children [62]. As with dexamethasone therapy,
maternal safety when prescribing salbutamol is
fundamental. In our own unit, therefore, mothers
are admitted for observation during initiation of
salbutamol therapy and a baseline 12 lead ECG,
plasma urea and electrolytes are undertaken.
The ECG and electrolytes are assessed at regular
intervals during the treatment period.Fetal and neonatal outcome
When assessing the rate of intra-uterine death,
the live birth rate and one year survival, studies
have indicated no statistical difference between
cohorts prenatally exposed to maternal dexameth-
asone when compared to those who received no
prenatal therapy [26,47]. In one study, both
cohorts had similar rates of fetal hydrops, fetal
ventricular escape rates and ventricular dysfunc-
tion [47]. Risk factors predicting a poorer outcome
in a fetus with congenital complete AV block have
been identified. These include a ventricular
escape rate 650 bpm, gestation at diagnosis
<20 weeks, fetal hydrops, and impaired left ven-
tricular function [6]. In the presence of such risk
factors, the risk of intrauterine death is 22%, and
neonatal mortality 18% in comparison to 2% and
3%, respectively in the absence of any risk factors
[47]. A report by Moak et al. [63] described 16 chil-
dren with congenital complete AV block who
developed late onset dilated left ventricular car-
diomyopathy despite adequate pacing. Three
quarters developed cardiac failure within the first
two years of life, myocardial histology demon-
strated fibrosis in eleven cases, and myocyte
degeneration in two cases. This study highlights
the importance of careful long term monitoring
of cardiac function even in children receiving
appropriate pacing for complete AV block [63].
In relation to fetal growth and development, a
European study suggested that fetuses of mothers
with anti-Ro/SSA 52 Kd antibodies and evidence
of second degree AV block or complete AV block
had a birth weight which was lower than those
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[64]. There was no statistical difference in the ges-
tational age of both cohorts. In addition, the
fetuses with second or complete AV block showed
no evidence of catch up growth during early child-
hood. In contrast, those with first degree AV block
or normal conduction demonstrated catch up
growth within the first two months of life. None
of the infants with a lower birth weight demon-
strated any gross cognitive impairment [64].
In neonatal lupus syndrome, the autoimmune
process not only affects the fetal conduction tis-
sue, but also the myocardium, papillary muscles
and valvular tissue, resulting in endocardial fibro-
elastosis (EFE). It should be noted that not all
fetuses affected by immune mediated complete
AV block have EFE and the converse is also true.
Immunohistochemical staining of EFE in complete
AV block demonstrates autoantibody deposition
[65]. Previously, EFE in this condition was
assumed to be a result of prolonged bradycardia
in utero, but has now been described as a separate
entity which may develop in both pre and postna-
tal periods. The postnatal prognosis must remain
guarded due to the potential development of late
congestive cardiac failure. Thus, neonatal lupus
erythematosis can present as EFE or complete
AV block, and these should probably be regarded
as separate disease entities [65].Future directions
New advances are being made in the form of
in vitro studies. Preliminary studies have identi-
fied a potential protective mechanism in the form
of b2-glycoprotein I. This glycoprotein is closely
associated with anti-phospholipid antibodies,
binding to Ro-60 on the surface of apoptotic cells.
Further study is require to assess the efficacy of
this potential therapy in a clinical setting [66–68].Conclusion
The general consensus within the scientific and
medical community is that the development of
immune mediated complete AV block is a multi-
factorial, autoimmune process. Clinicians are in
agreement that the presence of anti-Ro/SSA and
La/SSB are contributing factors to the develop-
ment of the disease but only as part of a more
complex autoimmune process. Screening for pre-
natal complete AV block remains a challenge as
the majority of women have no pre-existing clini-
cal features of connective tissue disease or a previ-
ous child with complete AV block. In summary,there is insufficient robust evidence to suggest
that prophylactic maternal therapy alters the inci-
dence or recurrence rate of congenital complete
AV block in the high risk population [69]. Further-
more, despite an increased incidence of complete
AV block in asymptomatic women, until more
robust scientific evidence is available, most clini-
cians will continue to refer women with antibody
positive connective tissue disease for fetal cardiol-
ogy surveillance during the second trimester to
monitor for the development and progression of
AV block. A further understanding of the patho-
physiology of complete AV block, in particular
disease progression, will guide therapy for lower
degrees of AV block, complete AV block and pre-
conception therapy. This will allow clinicians to
counsel parents more accurately and provide bet-
ter prognostication. There is consensus that multi-
center, prospective trials are required to answer
these questions.References
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